Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 262.16 USD -1.75% Market Closed
Market Cap: 34.1B USD

Intrinsic Value

The intrinsic value of one ALNY stock under the Base Case scenario is 184.46 USD. Compared to the current market price of 262.16 USD, Alnylam Pharmaceuticals Inc is Overvalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ALNY Intrinsic Value
184.46 USD
Overvaluation 30%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Alnylam Pharmaceuticals Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
ALNY
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for ALNY cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
US
Biotechnology
Market Cap
33.9B USD
IPO
May 28, 2004
US
Biotechnology
Market Cap
33.9B USD
IPO
May 28, 2004
Price
$false
EPS
$false
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Despite Alnylam’s leadership in RNAi therapies, the company’s path to consistent profitability is not guaranteed, given its reliance on a relatively small number of approved drugs and uncertainty around insurance coverage, which could constrain revenue growth.

Bull Theses

Alnylam’s first-to-market advantage in RNAi therapeutics positions it to capture significant market share in rare disease segments. Strong demand for its commercialized products, such as ONPATTRO and GIVLAARI, could drive robust revenue growth.

Show More Less
How do you feel about ALNY?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Alnylam Pharmaceuticals Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Alnylam Pharmaceuticals Inc

Current Assets 3.3B
Cash & Short-Term Investments 2.7B
Receivables 405.3m
Other Current Assets 195.5m
Non-Current Assets 944.7m
PP&E 693.9m
Other Non-Current Assets 250.8m
Efficiency

Free Cash Flow Analysis
Alnylam Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Alnylam Pharmaceuticals Inc

Revenue
2.2B USD
Cost of Revenue
-323.4m USD
Gross Profit
1.9B USD
Operating Expenses
-2.1B USD
Operating Income
-176.9m USD
Other Expenses
-101.3m USD
Net Income
-278.2m USD
Fundamental Scores

ALNY Profitability Score
Profitability Due Diligence

Alnylam Pharmaceuticals Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional ROE
ROE is Increasing
42/100
Profitability
Score

Alnylam Pharmaceuticals Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

ALNY Solvency Score
Solvency Due Diligence

Alnylam Pharmaceuticals Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Long-Term Solvency
Average Altman Z-Score
39/100
Solvency
Score

Alnylam Pharmaceuticals Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALNY Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast ALNY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALNY is 324.51 USD with a low forecast of 196.95 USD and a high forecast of 525 USD.

Lowest
Price Target
196.95 USD
25% Downside
Average
Price Target
324.51 USD
24% Upside
Highest
Price Target
525 USD
100% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Alnylam Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ALNY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ALNY Insider Trading
Buy and sell transactions by insiders

ALNY News

Other Videos
What is the Intrinsic Value of one ALNY stock?

The intrinsic value of one ALNY stock under the Base Case scenario is 184.46 USD.

Is ALNY stock undervalued or overvalued?

Compared to the current market price of 262.16 USD, Alnylam Pharmaceuticals Inc is Overvalued by 30%.

Back to Top